Nuveen
ATOS icon

Nuveen’s Atossa Therapeutics ATOS Stock Holding History

Nuveen’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-11,382
Closed -$115K – 3285
2025
Q1 		$115K Hold
11,382
– – ﹤0.01% 3203
2024
Q4 		$161K Hold
11,382
– – ﹤0.01% 3239
2024
Q3 		$260K Hold
11,382
– – ﹤0.01% 3178
2024
Q2 		$203K Buy
+11,382
New +$252K ﹤0.01% 3213
2022
Q2 		– Sell
-135,157
Closed -$3.18M – 3251
2022
Q1 		$3.18M Buy
135,157
+32,457
+32% +$659K ﹤0.01% 2289
2021
Q4 		$2.87M Sell
102,700
-3,564
-3% -$130K ﹤0.01% 2390
2021
Q3 		$5.71M Buy
106,264
+33,122
+45% +$1.93M ﹤0.01% 2129
2021
Q2 		$6.93M Buy
+73,142
New +$3.87M ﹤0.01% 2078

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Nuveen's ATOS Position: Q2 2025 in Review

Nuveen sold out of Atossa Therapeutics (ATOS) in Q2 2025, closing a stake of 11,382 shares — an estimated $115K sold.

Nuveen first reported a position in ATOS in Q2 2021 and held it in 8 quarters. The position peaked at $6.93M in Q2 2021. 84 funds tracked by Wall St. Rank hold ATOS as of Q2 2025.

  • Nuveen reported no remaining Atossa Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Nuveen sold 11,382 Atossa Therapeutics shares in Q2 2025, an estimated $115K.
  • Nuveen first reported a position in Atossa Therapeutics in Q2 2021 and held it in 8 quarters.
  • Nuveen's Atossa Therapeutics position peaked at $6.93M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Atossa Therapeutics as of Q2 2025.

Based on Nuveen's 13F filing for Q2 2025, filed 12 Aug 2025.